ARTICLE | Company News
Heptares, Shire deal
March 26, 2012 7:00 AM UTC
Shire exercised a 2011 option to license exclusive, worldwide rights from Heptares to a preclinical adenosine A2A receptor (ADORA2A) antagonist. Heptares receives undisclosed upfront payments and is ...